Sangyeul Han founded INGENIA Therapeutics in 2018.
Previously, he worked at Cell Signaling Technology where he led its Antibody Technology and Molecular Biology groups. Before CST, he worked for the Institute for Basic Science as a research fellow investigating vascular biology and Samsung Advanced Institute of Technology, where he led a project for the development of therapeutic antibodies for multiple diseases.

He finished his post-doctoral training at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) where he studied the pathological mechanisms of several tumor suppressor syndromes. He also worked as an instructor at MGH/HMS. He has authored over 20 publications in scientific journals and holds multiple patents in the areas of therapeutic antibody development.

Sangyeul holds B.S., M.S., and Ph.D. degrees from Seoul National University, South Korea where his graduate research focused on investigating the regulatory mechanism of secretory protein trafficking in mammalian cells.

Laurens Bouckaert is an independent biotech executive with over 20 years of experience in sales and marketing (US, EU) who currently focuses on providing commercial strategic support to small and mid-cap companies. During the last 10 years, Laurens has been active within the ophthalmology space with proven results in aligning and executing on strategic objectives across global and regional marketing teams, market access, medical affairs, R&D and supply chain, including managing US and Global marketing. More recently Laurens has taken on BD roles. Before this, he worked across multiple therapeutic areas including vaccines, rheumatology, cardiovascular and asthma at GSK and Merck& Co.

Laurens has a Masters in Pharmaceutical Science from Vrije Universiteit Brussel (Belgium) and a MBA in Marketing Management from Vlerick Business School (Belgium).

Jinsam You joined INGENIA Therapeutics in 2022.
Previously, he worked at Eli Lilly and company where he led the early stage of drug development programs. He made numerous contributions on immunogenicity risk assessment, antibody engineering, and biomarker strategy.
Prior to his tenure with Eli Lilly, he served as a lecturer and scientific director at the Indiana university school of medicine. He also worked at a protein research startup called Monarch Life Sciences LLC where he led a biomarker discovery and assay development group.

Jinsam obtained his Ph.D. degree in biochemistry and molecular biology from Pusan National University, South Korea and did post-doctoral training at Indiana university school of medicine.

Stephen Berasi joined INGENIA in September 2024.

Previously he worked 20 years at Wyeth and Pfizer in Cambridge, MA leading teams focusing on biotherapeutic discovery and development across therapeutic areas including musculoskeletal biology, inflammatory disorders, fibrotic disease, pulmonary hypertension, and kidney disease with a focus on glomerular disease and podocyte biology.
His tenure included 10 years leading a diverse team of scientists at Pfizer’s Centers for Therapeutic Innovation (CTI) which collaborated directly with academic institutions and investigators to accelerate concepts into viable therapies with breakthrough potential for patients. Stephen and his team drove multiple programs into clinical development including phase 2 and 3. He also mentored postdoctoral fellows and has 18 publications and holds multiple patents.
Stephen has a B.S. from Boston College and a Ph.D. from the Tufts University Graduate School of Biomedical Sciences in Boston.

Peter Park joined INGENIA Therapeutics in 2020.
Before joining INGENIA, Peter worked at Genosco Inc. where he was Director and Treasurer. Prior to Genosco, Peter worked at Acushnet Company for 7+ years and held financial planning and investor relations positions. In those roles at Acushnet, Peter was the lead contact for private equity investors in South Korea and was instrumental in bringing the company to a successful IPO at NYSE in 2016. Peter also spent time earlier in his career working for a venture capital firm and a family office as an accounting & tax manager.

Peter is a Certified Public Accountant and holds an M.S.A. from the University of Illinois and a B.A. in Russian Language & Literature from Korea University.

Eric Furfine joined INGENIA’s SAB in 2021.
He is also a member of the board of directors of INGENIA. He is co-CEO & CSO of Mosaic Biosciences, INGENIA’s research partner and previously held various leadership roles in biotechnology and pharmaceutical companies, including GSK, Regeneron and BMS.
Eric advises INGENIA on pre-clinical development and corporate strategy.

Leo Kim joined INGENIA’s SAB in 2021.
He is an assistant professor of Ophthalmology at Harvard Medical School and a retina surgeon at the Massachusetts Eye and Ear.
He is a full time member of the Retina Service with extensive experience in the management of retinal diseases associated with neovascularization or angiogenesis including retinal vein occlusions, diabetic retinopathy, and age-related macular degeneration.

Patricia D’Amore joined INGENIA’s SAB in 2021.
She is a professor and vice-chair of Basic and Translational Research at Harvard Medical School. Dr. D’Amore is an internationally recognized expert of vascular growth and development and has been at the forefront of angiogenesis research for over three decades. Her current research focuses on understanding the regulation of the development and stabilization of the microvasculature and investigating the pathogenesis of AMD with a focus on inflammation.

Tariq Ghayur joined INGENIA’s SAB in 2022.
He retired from AbbVie (July 2021) as a Distinguished Research Fellow and currently works as an independent consultant.
He has 30+ years’ experience leading multi-disciplinary Biologics discovery programs and developing novel bi- and multi-specific Biologics platforms. Several programs are in various stages of discovery/development pipeline. His research focused on immune modulation for autoimmune and oncology indications and internalization and intracellular trafficking of antibody-receptor complexes.

Thomas M. Coffman joined INGENIA’s SAB in September 2021.
He is a professor at Duke University Medical Center and served as president of the American Society of Nephrology. His research focuses on the mechanisms of kidney injury in disease states and the role of the kidney in regulation of blood pressure.
His research addresses issues that are relevant to chronic disorders such as hypertension, diabetic nephropathy, transplant rejection, and autoimmune diseases.

Ho Min Kim joined INGENIA’s SAB in September 2024.
He is a professor at the Korea Advanced Institute of Science and Technology (KAIST) and formerly served as the Chief Investigator of the Center for Biomolecular & Cellular Structure at the Institute for Basic Science (IBS).
His research focuses on the molecular mechanisms of disease-related protein complexes using advanced structural biology techniques, including Cryo-EM and X-ray crystallography. He has also developed therapeutic protein candidates targeting cancer, cancer cachexia, age-related macular degeneration, and infectious diseases.
Prof. Kim has received numerous prestigious honors, including the Korean Presidential Young Scientist Award and the Asan Award in Medicine for Young Biomedical Scientists.

Namrata Saroj, OD has over 20 years of experience focusing on global development and commercialization of new drugs and technologies advancing Ophthalmic care. Currently, Dr. Saroj is the Chief Business Officer at Ocular Therapeutix. She also advises companies on strategic partnerships, clinical development and commercialization support. She is the co-founder and Chief Medical Advisor of Clinical Trials Resource Group, a CRO focused on executing Ophthalmology clinical trials. Prior to this, she led the Ophthalmology Medical Affairs team as an Executive Director at Regeneron Pharmaceuticals, Inc and was integrally involved in the global commercialization of Eylea. Dr. Saroj has previously held positions at Genentech and Manhattan Eye, Ear & Throat Hospital.

Dr. Saroj advises INGENIA on clinical development strategy.

Dr. Robert Avery is a distinguished retina specialist and surgeon based in Santa Barbara, California, and the founder and CEO of California Retina Consultants, a practice that later became part of Retina Consultants of America. Trained at the Johns Hopkins Wilmer Eye Institute and Duke University, he has been a pioneer in angiogenesis research and among the first to introduce anti-VEGF therapies such as bevacizumab (Avastin) and ranibizumab (Lucentis) into clinical practice.

He co-founded the California Retina Research Foundation, which supports extensive clinical trials and national research in gene therapy, stem cell therapy, and ocular drug delivery. Dr. Avery has authored numerous publications, holds patents in retinal drug delivery, and is widely recognized for his leadership in clinical research, innovation, and the advancement of retinal care.

Dr. Charlie Wyckoff is a highly respected retina specialist based in Houston, serving as Vice Chair of Ophthalmology at Houston Methodist Hospital and a key member of Retina Consultants of Houston, where he leads major clinical trial programs. His clinical and research interests span age-related macular degeneration, diabetic retinopathy, and the development of innovative imaging and therapeutic technologies.

Dr. Wyckoff has led numerous clinical studies advancing diagnostic and treatment approaches for retinal diseases, including emerging therapies for diabetic macular edema and macular degeneration. He is widely recognized for his clinical excellence, leadership in clinical research, rapid integration of cutting-edge diagnostic tools, and compassionate patient care—establishing him as a leading figure in retinal medicine in Houston.

Dr. Yu is a leading physician-scientist in cardiovascular medicine and serves as Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. He earned his MD and PhD from Duke University, completed residency at UCSF, and trained in cardiovascular medicine and research at MGH.

His research focuses on how cytokine growth factor pathways regulate cardiovascular homeostasis, injury, and regeneration, and his lab has pioneered new models and molecular tools in this field. Dr. Yu is widely recognized for his impactful research, clinical expertise, and leadership in translational cardiology.

Dr. Yon Su Kim is a leading figure in nephrology and transplant immunology in Korea, serving as Professor of Medicine at Seoul National University College of Medicine. He earned his MD, MS, and PhD from Seoul National University and expanded his international research experience as a postdoctoral fellow at Harvard Medical School. His clinical and research work spans chronic kidney disease, glomerulonephritis, lupus nephritis, diabetic kidney disease, dialysis care, and immune regulation after kidney transplantation.

Dr. Kim has led influential research programs focused on mechanisms of immune tolerance and novel therapeutic strategies in transplantation, while also demonstrating exceptional leadership as former Vice Dean of Academic and Educational Affairs and as President & CEO of Seoul National University Hospital from 2019 to 2023. Recognized with major awards in Korea and abroad—including becoming the first Korean recipient of the AST Young Investigator Award—he is widely respected for his contributions to patient care, medical education, and the advancement of kidney and transplant science.